Trial Profile
Phase II Multicentre, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Avelumab With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Unresectable or Metastatic Urothelial Carcinoma (UC) Who Have Not Received Prior Systemic Therapy and Who Are Ineligible to Receive Cisplatin-based Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Gemcitabine
- Indications Bladder cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms INDUCOMAIN
- 27 Apr 2021 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 27 Apr 2021 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.
- 21 Sep 2020 Status changed from active, no longer recruiting to completed.